170 related articles for article (PubMed ID: 37247420)
1. Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States.
Goshua G; Calhoun C; Ito S; James LP; Luviano A; Krishnamurti L; Pandya A
Ann Intern Med; 2023 Jun; 176(6):779-787. PubMed ID: 37247420
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States : A Cost-Effectiveness Analysis.
Basu A; Winn AN; Johnson KM; Jiao B; Devine B; Hankins JS; Arnold SD; Bender MA; Ramsey SD
Ann Intern Med; 2024 Feb; 177(2):155-164. PubMed ID: 38252942
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease.
Salcedo J; Bulovic J; Young CM
Sci Rep; 2021 May; 11(1):10838. PubMed ID: 34035408
[TBL] [Abstract][Full Text] [Related]
4. Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers.
Meunier A; Longworth L; Gomes M; Ramagopalan S; Garrison LP; Popat S
Pharmacoeconomics; 2023 Aug; 41(8):1011-1025. PubMed ID: 37296369
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis.
Kowal S; Ng CD; Schuldt R; Sheinson D; Cookson R
Value Health; 2023 Feb; 26(2):216-225. PubMed ID: 36192293
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.
Herring WL; Gallagher ME; Shah N; Morse KC; Mladsi D; Dong OM; Chawla A; Leiding JW; Zhang L; Paramore C; Andemariam B
Pharmacoeconomics; 2024 Jun; 42(6):693-714. PubMed ID: 38684631
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
[No Abstract] [Full Text] [Related]
10. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
Le P; Rothberg MB
Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
13. Decreasing alloimmunization-specific mortality in sickle cell disease in the United States: Cost-effectiveness of a shared transfusion resource.
Ito S; Pandya A; Hauser RG; Krishnamurti L; Stites E; Tormey C; Krumholz HM; Hendrickson JE; Goshua G
Am J Hematol; 2024 Apr; 99(4):570-576. PubMed ID: 38279581
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States.
Simons CL; Malone D; Wang M; Maglinte GA; Inocencio T; Wade SW; Bennison C; Shah B
J Med Econ; 2021; 24(1):421-431. PubMed ID: 33634729
[TBL] [Abstract][Full Text] [Related]
15. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
[TBL] [Abstract][Full Text] [Related]
16. Preimplantation genetic testing for sickle cell disease: a cost-effectiveness analysis.
Combs JC; Dougherty M; Yamasaki MU; DeCherney AH; Devine KM; Hill MJ; Rothwell E; O'Brien JE; Nelson RE
F S Rep; 2023 Sep; 4(3):300-307. PubMed ID: 37719105
[TBL] [Abstract][Full Text] [Related]
17. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States.
Biskupiak JE; Ramos M; Levy CJ; Forlenza G; Hopley C; Boyd J; Swift D; Lamotte M; Brixner DI
J Manag Care Spec Pharm; 2023 Jul; 29(7):807-817. PubMed ID: 37133431
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
